# Demo run ts-0e0075

Output of `npx tsx scripts/demo.mts` (5 turns, 3 sessions, one user) followed by `npx tsx scripts/report.mts ts-0e0075`. Claude Haiku 4.5 on Bedrock, temperature 0.

## Report

### Per session

| session_id | llm_calls | input_tokens | output_tokens | cache_read_tokens | cost_usd | tool_calls | tool_errors | llm_ms | tool_ms |
|---|---|---|---|---|---|---|---|---|---|
| ts-0e0075-a | 6 | 20092 | 874 | 0 | 0.02446 | 6 | 0 | 18062 | 201 |
| ts-0e0075-b | 4 | 8358 | 477 | 0 | 0.01074 | 2 | 0 | 8418 | 84 |
| ts-0e0075-c | 3 | 5669 | 359 | 0 | 0.00746 | 2 | 0 | 5798 | 83 |

### Per tool

| tool | calls | errors | p50_ms | p95_ms | avg_result_chars |
|---|---|---|---|---|---|
| search_papers | 9 | 0 | 41.9 | 61.1 | 3656 |
| remember | 1 | 0 | 17.8 | 17.8 | 5 |

### LLM latency

| model | calls | p50_ms | p95_ms | ttft_p50_ms | ttft_p95_ms | out_tok_p50 |
|---|---|---|---|---|---|---|
| global.anthropic.claude-haiku-4-5-20251001-v1:0 | 13 | 1511 | 8191 | 982 | 1953 | 88 |

## Transcript

```text

[ts-0e0075-a] > I'm a pharmacist and I only care about human clinical evidence, not mouse studies. Does vitamin D supplementation reduce the risk of fractures?
  tools: search_papers, remember, search_papers, search_papers · first text 3241 ms · total 8562 ms
Let me search more specifically for vitamin D supplementation trials:Let me try a more direct search:Based on my search of the SciFact abstracts, I found limited direct evidence on vitamin D supplementation alone for fracture prevention. The most relevant result is a review on optimal serum vitamin D concentrations [4462079], which suggests that serum 25(OH)D concentrations beginning at 75 nmol/L (30 ng/mL) are associated with better outcomes for fracture risk, with optimal levels between 90-100 nmol/L.

However, the abstracts available don't contain detailed results from large randomized controlled trials specifically testing vitamin D supplementation as a standalone intervention for fracture prevention in humans. The search results primarily returned studies on other osteoporosis treatments (bisphosphonates like alendronate and risedronate) rather than vitamin D supplementation trials.

To give you a definitive answer based on human clinical evidence, I'd need access to abstracts from major vitamin D supplementation trials (such as the VITAL study or D-Health trial). The SciFact database appears to have limited coverage of vitamin D-specific fracture prevention trials. I'd recommend consulting systematic reviews and meta-analyses from sources like the Cochrane Database for comprehensive human clinical evidence on this question.

[ts-0e0075-a] > What about in elderly people specifically?
  tools: search_papers, search_papers · first text 2565 ms · total 9784 ms
Unfortunately, the SciFact database doesn't appear to contain specific human clinical trials on vitamin D supplementation for fracture prevention in elderly populations. 

The most relevant evidence I found is the review on optimal serum vitamin D concentrations [4462079], which indicates that serum 25(OH)D concentrations of 75-100 nmol/L (30-40 ng/mL) are associated with better outcomes for fracture risk across populations. However, this doesn't directly address whether supplementation reduces fracture risk in elderly people specifically.

The other results discuss vitamin D deficiency in postmenopausal women [9555784] and general vitamin D insufficiency [23267371], but don't provide clinical trial data on supplementation efficacy for fracture prevention in the elderly.

As a pharmacist focused on human clinical evidence, you'd likely want to consult major clinical trial registries or systematic reviews (such as Cochrane) for landmark studies like the VITAL trial or other large RCTs specifically examining vitamin D supplementation in elderly populations, as these don't appear to be well-represented in this particular abstract database.

[ts-0e0075-b] > Is there evidence that statins affect cancer risk?
  tools: search_papers, search_papers · first text 1538 ms · total 7246 ms
I'll search for evidence on statins and cancer risk.Let me search more specifically for clinical evidence on statins and cancer outcomes.Based on the search results, I found limited direct evidence in this database about statins and cancer risk in human clinical trials. However, here's what the available evidence shows:

**Key Finding:**
One systematic review [1522336] notes that "recent retrospective analyses have suggested that statins also prevent cancer," but this review focused on *in vitro* (laboratory) studies of statins' anti-tumor effects on head and neck squamous cell carcinoma—not human clinical evidence.

**Important Limitation:**
The large meta-analysis of randomized controlled trials [5698494] examining statins' benefits in primary prevention of cardiovascular disease does not appear to report cancer outcomes as a primary finding in the abstract.

**Bottom Line:**
While there are retrospective observational analyses suggesting a potential cancer-preventive effect, the SciFact database doesn't contain strong human clinical trial evidence specifically examining whether statins affect cancer risk. The evidence that does exist appears to be mostly from laboratory studies or observational data rather than randomized controlled trials.

As a pharmacist focused on clinical evidence, you'd want to look for prospective cohort studies or RCTs that specifically tracked cancer incidence as an outcome in statin users versus controls—which doesn't appear to be well-represented in these abstracts.

[ts-0e0075-b] > Summarise that in two sentences.
  tools: none · first text 875 ms · total 1288 ms
Recent retrospective analyses suggest statins may prevent cancer, but this is primarily supported by laboratory studies rather than human clinical trials [1522336]. The SciFact database lacks robust randomized controlled trial evidence specifically examining whether statins affect cancer risk in patients.

[ts-0e0075-c] > Do beta blockers help after a heart attack?
  tools: search_papers, search_papers · first text 753 ms · total 5898 ms
I'll search for evidence on beta blockers after heart attack.Let me search more specifically for beta blocker benefits after myocardial infarction.Based on the search results, I found limited specific evidence in this database about beta blockers after heart attack. However, one abstract does provide relevant information:

**Beta blockers improve survival in left ventricular systolic dysfunction** [24586989]. The abstract notes that "betaAR blockade improves survival in left ventricular systolic dysfunction," which is a common consequence of myocardial infarction.

The evidence in this database is somewhat limited on this specific question. The available data supports that beta blockers provide survival benefits in heart failure (which often develops after MI), but I'd recommend consulting clinical guidelines like those from the ACC/AHA or ESC, which have more comprehensive evidence on post-MI beta blocker therapy. These guidelines generally recommend beta blockers as standard therapy after myocardial infarction for most patients, particularly those with reduced ejection fraction.
```
